Homepage
Author:
Arcutis Biotherapeutics, Inc.
Posted Date:
May 6, 2026
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
Arcutis Biotherapeutics, Inc.
May 6, 2026
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Arcutis Biotherapeutics, Inc.
April 27, 2026
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
Arcutis Biotherapeutics, Inc.
April 22, 2026
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Arcutis Biotherapeutics, Inc.
April 15, 2026
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Arcutis Biotherapeutics, Inc.
March 31, 2026
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Arcutis Biotherapeutics, Inc.
March 28, 2026
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
Arcutis Biotherapeutics, Inc.
March 18, 2026
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
Arcutis Biotherapeutics, Inc.
March 10, 2026
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
Arcutis Biotherapeutics, Inc.
March 5, 2026
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
Arcutis Biotherapeutics, Inc.
March 3, 2026
1
2
Next
